All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2023-05-26T09:10:44.000Z

Is combination ATG + PTCy prophylaxis always preferable to using each agent separately in haplo-HCT?

May 26, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in GvHD.

Bookmark this article

During the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Abdul-Hamid Bazarbachi, Jacobi Medical Centre, New York, US. We asked, Is combination anti-thymocyte globulin (ATG) + post-transplantation cyclophosphamide (PTCy) prophylaxis always preferable to using each agent separately in haploidentical hematopoietic cell transplant (haplo-HCT)?

Is combination ATG + PTCy prophylaxis always preferable to using each agent separately in haplo-HCT?

Bazarbachi begins by outlining the indications and efficacy of both high-dose PTCy and ATG as sole therapies in GvHD prophylaxis. He goes on to discuss recent clinical research presented at the 49th Annual Meeting of the EBMT on the use of these treatments concurrently, with a focus on engraftment, relapse, and overall survival. Bazarbachi concludes by describing the implications of this data for the management of patients post haplo-HCT and the resulting incidence of GvHD.

Your opinion matters

HCPs, what is your preferred format for educational content on the GvHD Hub?
4 votes - 40 days left ...

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox